Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc. reported a remarkable 41.6% year-over-year revenue growth in the fourth quarter, exceeding estimates by 1.5%. Anticipated margin improvements in 2026 and 2027, driven by partnerships and contract maturation, suggest a potential return to margins of 12% to 15%. Additionally, the company has successfully added significant capitated revenue, projecting long-term growth opportunities, particularly in new markets and a gradual shift to value-based care, which bodes well for sustained earnings growth.

Bears say

The Oncology Institute's financial outlook appears negative due to a significant year-over-year decline of 71.4% in revenue from Clinical Trials & Other segments, which has materially affected overall financial performance. Adjusted EBITDA of $0.1 million, falling short of estimates, reflects a troubling gross margin of just 0.1%, largely driven by contract losses that are anticipated to continue impacting margins into 2026 and 2027. Additionally, a $15 million headwind from eliminated DIR fees negatively affected dispensary margins, compounded by a growth trend in the oncology industry that the company expects to be well below the general market range of 11-14%.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Mar 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.